Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Return on Capital Employed (2022 - 2026)

Centessa Pharmaceuticals has reported Return on Capital Employed over the past 4 years, most recently at 39.56% for Q4 2025.

  • Quarterly Return on Capital Employed fell 200.0% to 39.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 39.56% through Dec 2025, down 200.0% year-over-year, with the annual reading at 35.25% for FY2025, 1373.0% up from the prior year.
  • Return on Capital Employed was 39.56% for Q4 2025 at Centessa Pharmaceuticals, up from 48.47% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 33.83% in Q3 2024 and troughed at 52.72% in Q1 2023.
  • The 4-year median for Return on Capital Employed is 48.47% (2025), against an average of 45.57%.
  • Year-over-year, Return on Capital Employed surged 1692bps in 2024 and then crashed -1464bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 50.12% in 2022, then fell by -4bps to 52.0% in 2023, then rose by 28bps to 37.56% in 2024, then decreased by -5bps to 39.56% in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Return on Capital Employed are 39.56% (Q4 2025), 48.47% (Q3 2025), and 42.98% (Q2 2025).